(BUSINESS WIRE)--Five Prime Therapeutics, Inc. is a clinical stage, privately-held company discovering and developing innovative protein and antibody therapeutics. Using its world-class biologics discovery platform, FivePrime is building a strong product pipeline in oncology, immunology and metabolic diseases. It has engineered a unique suite of technologies to comprehensively mine the entire extracellular human proteome - the complete collection of secreted proteins and receptors - to discover its therapeutic protein drugs and antibody targets. FivePrime is currently in Phase I with FP-1039 for solid tumors. Pharmaceutical partners include Johnson & Johnson’s Centocor division and Pfizer, Inc.
